Amplia Therapeutics Health Care
Biotech Cancer Healthcare

$0.076 -0.001 (-1.30%)

High $0.08	Low $0.07	Trades 8	Turnover $9,058	Volume 120,981
30 June 2023 at 2:59pm

If you were already registered, log in here.

Market Cap (13-Nov) $46,198,080 (1,444th)	Close (30-Jun) $0.076 0 (0%)	Volume (30-Jun) 120,981	Shortsold (9-Nov) 30,144 (0.01%) (594th)
52w High $0.275	52w Low $0.076	P/E -	EPS -0.02

Short Interest

ASIC data, 9 Nov 2026

% Shorted

0.01%

vs 0.01% prior report

Most Shorted Rank

594th

of 711 shorted ASX stocks

Peak Short

0.23%

Nov 2024

Days to Cover

0.0

at 50d avg vol

View full short position history →

	Subject
	ATX ATX Ann: AMP945 International Nonproprietary Name Narmafotinib
	1 (current) 2 3
	ATX ATX Ann: Amplia AGM to be held Thursday 24 August 2023
	ATX ATX Ann: Key to Corporate Governance Disclosures
	ATX ATX Ann: 2023 Corporate Governance Statement
	ATX ATX Ann: Annual Report to Shareholders
	ATX ATX Ann: AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
	ATX ATX Ann: Grant to collaborate with CSIRO Supplementary Announcement
	ATX ATX Ann: Amplia receives grant to collaborate with CSIRO
	ATX ATX Ann: ACCENT Trial Recruitment Progress
	ATX ATX Ann: Quarterly Activities and Cashflow Reports - March 23 Qtr
	ATX ATX Ann: First Patient Recruited to Cohort 3 of ACCENT Trial
	ATX ATX Ann: Dose Escalation Approved in ACCENT Clinical Trial of AMP945
	ATX ATX Ann: ACCENT Trial Recruitment Progress
	ATX ATX Ann: ATX - US Conference Presentation
	ATX ATX Ann: AmpliaTherapeutics - Lorne Cancer Conference Presentation
	ATX ATX Ann: First Patient Recruited to Cohort 2 of Accent Trial
	ATX ATX Ann: Quarterly Activities and Cashflow Reports - December 2022
	ATX ATX Ann: Dose Escalation Approved in ACCENT Clinical Trial of AMP945
	ATX ATX Ann: Letter to Shareholders End of Year Summary and 2023 Plans
	ATX ATX Ann: Final Director's Interest Notice - Dr. John Lambert
	ATX ATX Ann: ACCENT Trial Recruitment Progress
	ATX ATX Ann: Appendix 4D and Financial Report Half Year ended 30 Sep 22
	ATX ATX Ann: Amplia Appoints Dr Christopher Burns CEO & Managing Director
	ATX ATX Ann: Quarterly Activities and Cashflow Reports - Sep 2022 Qtr
	ATX ATX Ann: Notification regarding unquoted securities - ATX
	ATX ATX Ann: AMP886 Activity in Acute Myeloid Leukemia
	ATX ATX Ann: AACR Conference Presentation
	ATX ATX Ann: CEO Resignation
	ATX ATX Ann: Notification regarding unquoted securities - ATX
	ATX ATX Ann: Change of Director's Interest Notice - Dr. Warwick Tong
	ATX ATX Ann: Change of Director's Interest Notice - Dr. Robert Peach
	ATX ATX Ann: Change of Director's Interest Notice - Dr. Christopher Burns
	ATX ATX Ann: Change of Director's Interest Notice - Mrs. Jane Bell
	ATX ATX Ann: Change of Director's Interest Notice - Dr. John Lambert
	ATX ATX Ann: Notification of cessation of securities - ATX
	ATX ATX Ann: Amplia Receives $1.8m R&D Tax Incentive
	ATX ATX Ann: Results of Annual General Meeting
	ATX ATX Ann: CEO & Managing Director Presentation to AGM
	ATX ATX Ann: Annual General Meeting - ESOP and New Constitution
	ATX ATX Ann: Employee Security Ownership Plan
	ATX ATX Ann: Change of Director's Interest Notice - Dr. Warwick Tong
	ATX ATX Ann: First Patient Recruited to ACCENT Trial in Pancreatic Cancer
	ATX ATX Ann: Quarterly Activities and Cashflow Reports - June 2022 Qtr
	ATX ATX Ann: Presentation at Major Pancreatic Cancer Conference
	ATX ATX Ann: Notice of Annual General Meeting/Proxy - YE 31 March 2022
	ATX ATX Ann: Change of Director's Interest Notice - Dr. Chistopher Burns
	ATX ATX Ann: Change of Director's Interest Notice - Dr. Robert Peach
	ATX ATX Ann: Change of Director's Interest Notice - Dr. John Lambert
	ATX ATX Ann: Change of Director's Interest Notice - Dr. Warwick Tong
	ATX ATX Ann: Notification of cessation of securities - ATX

If you were already registered, log in here.

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Mesoblast

MSB

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

Telix Pharmaceuticals

TLX

Upcoming Floats (8)

MATRIX CRITICAL MINERALS LIMITED

MTX

SUPER MINERALS LTD

S88

MAVERICK URANIUM LIMITED

MAV

Fitgenes

ATW $7.5m raise

RIO DE ORO CORP LTD

RDO $30m raise

Adbri Ltd

ABC $5m raise

RAMSAY GENERALE DE SANTE SA

RGS

Gratifii

MBM

Top

End of Day Prices

Date	Close	Volume	Change
13-Nov	$0.09	741,841	+0.00 (4.65%)
12-Nov	$0.09	242,966	0.00 (1.15%)
11-Nov	$0.09	877,174	+0.01 (7.41%)
10-Nov	$0.08	917,757	0.00 (1.22%)
09-Nov	$0.08	414,269	-0.01 (7.87%)
06-Nov	$0.09	706,919	0.00 (1.11%)
05-Nov	$0.09	1,209,884	+0.00 (1.12%)
04-Nov	$0.09	531,430	+0.00 (5.95%)
03-Nov	$0.08	462,156	0.00 (0.00%)
02-Nov	$0.08	736,376	0.00 (0.00%)
30-Oct	$0.08	1,154,303	0.00 (5.62%)
29-Oct	$0.09	602,933	+0.01 (7.23%)
28-Oct	$0.08	339,346	+0.00 (5.06%)
27-Oct	$0.08	315,976	+0.00 (1.28%)
26-Oct	$0.08	269,970	0.00 (2.50%)
7 up, 6 down, and 2 flat days

Amplia Therapeutics Health Care
Biotech Cancer Healthcare

Short Interest

Followers

Prices

Announcements

Similar Companies

Upcoming Floats (8)

End of Day Prices

Amplia Therapeutics Health Care Biotech Cancer Healthcare

Short Interest

Followers

Prices

Announcements

Similar Companies

Upcoming Floats (8)

End of Day Prices

Amplia Therapeutics Health Care
Biotech Cancer Healthcare